Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich to Market Protein Arrays Made by Procognia

NEW YORK, Nov. 9 (GenomeWeb News) - Sigma-Aldrich will market human protein arrays developed by Procognia, the companies said today.

Procognia has developed a tag technology to create arrays of biologically related human proteins that retain their native functions in the array format, the companies said. The first array will contain wild type human p53 and its germline SNP variants.


Procognia's SNP-variant proteins will enable researchers to investigate the mechanism of cancer progression on many proteins in parallel, the company said.


Additional protein arrays, expected to launch "in the coming months," will contain "selected sets of biologically related human proteins including collections of proteins associated with key diseases including cancer and signal transduction," according to a statement.


Financial terms of the exclusive collaboration were not disclosed.


Separately, Sigma said it has declared a quarterly cash dividend of $.17 per share. The dividend is payable on Dec. 15 to shareholders of record on Dec. 1, 2004.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.